CLLS Cellectis S.A. gains 18% Nov 20, 2019

Developing cancer immunotherapies based on gene-edited CAR T-cells.http://www.priceseries.com/trade/CLLS-Cellectis-SA-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019102520191120.html

Posted by : priceSeries Wednesday, November 20, 2019

Subscribe by Email

Follow Updates Articles from This Blog via Email